Ameriprise Financial Inc. Boosts Holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB)

Ameriprise Financial Inc. boosted its position in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) by 191.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 151,862 shares of the medical instruments supplier's stock after buying an additional 99,819 shares during the period. Ameriprise Financial Inc. owned 2.80% of Mesa Laboratories worth $20,026,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. Amundi increased its position in shares of Mesa Laboratories by 81.6% during the fourth quarter. Amundi now owns 661 shares of the medical instruments supplier's stock worth $91,000 after purchasing an additional 297 shares in the last quarter. Resona Asset Management Co. Ltd. acquired a new stake in Mesa Laboratories during the 4th quarter worth $92,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Mesa Laboratories during the fourth quarter worth $132,000. Tower Research Capital LLC TRC raised its position in shares of Mesa Laboratories by 72.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,328 shares of the medical instruments supplier's stock valued at $175,000 after buying an additional 560 shares during the last quarter. Finally, Berry Wealth Group LP lifted its stake in shares of Mesa Laboratories by 5.3% in the fourth quarter. Berry Wealth Group LP now owns 1,657 shares of the medical instruments supplier's stock worth $219,000 after buying an additional 83 shares in the last quarter. Institutional investors and hedge funds own 90.60% of the company's stock.

Mesa Laboratories Price Performance

MLAB traded down $3.87 on Monday, reaching $118.55. 42,379 shares of the company's stock were exchanged, compared to its average volume of 39,860. Mesa Laboratories, Inc. has a twelve month low of $83.68 and a twelve month high of $155.12. The stock has a market cap of $644.20 million, a PE ratio of -2.56 and a beta of 0.97. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.71 and a quick ratio of 0.53. The stock's fifty day moving average price is $118.33 and its 200-day moving average price is $126.83.

Mesa Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, June 16th. Investors of record on Friday, May 30th will be issued a $0.16 dividend. The ex-dividend date is Friday, May 30th. This represents a $0.64 annualized dividend and a dividend yield of 0.54%. Mesa Laboratories's dividend payout ratio is presently -1.38%.

Insider Buying and Selling

In other Mesa Laboratories news, CEO Gary M. Owens sold 21,000 shares of the firm's stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $123.91, for a total value of $2,602,110.00. Following the completion of the sale, the chief executive officer now directly owns 43,337 shares of the company's stock, valued at $5,369,887.67. This trade represents a 32.64% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.40% of the stock is currently owned by company insiders.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.